Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Percheron Therapeutics ( (AU:PER) ) is now available.
Percheron Therapeutics has secured an exclusive worldwide license from Hummingbird Bioscience for HMBD-002, a phase II-ready immuno-oncology drug candidate targeting VISTA, a novel checkpoint in cancer treatment. This strategic move positions Percheron to advance in the immuno-oncology field, with plans to initiate clinical trials in 2026, potentially offering new therapeutic options for cancer patients.
The most recent analyst rating on (AU:PER) stock is a Buy with a A$0.24 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an international biotechnology company focused on developing novel therapies for oncology and rare diseases.
Average Trading Volume: 2,079,348
Technical Sentiment Signal: Sell
Current Market Cap: A$10.87M
For detailed information about PER stock, go to TipRanks’ Stock Analysis page.